| Dr Catherine M Chua, DO | |
|
812 Gorman Ave, Elkins, WV 26241-3181 | |
| (304) 637-0433 | |
| (304) 637-0435 |
| Full Name | Dr Catherine M Chua |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 812 Gorman Ave, Elkins, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295726685 | NPI | - | NPPES |
| 1842049000 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1965 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wv Caring | Arthurdale, WV | Hospice |
| Mountain Hospice, Inc. | Belington, WV | Hospice |
| Davis Medical Center | Elkins, WV | Hospital |
| West Virginia University Hospitals | Morgantown, WV | Hospital |
| Elkins Regional Convalescent Center | Elkins, WV | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Davis Memorial Hospital | 3072418540 | 69 |
News Archive
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda (memantine hydrochloride) tablets, 5mg and 10mg.
"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.
Blue Cross and Blue Shield in Michigan won a hospital pricing antitrust case. In Minnesota, nonprofit insurer UCare prepares to return $8 million to the state while Blue Cross and Blue Shield of Minnesota's profit rose 20 percent in 2011.
› Verified 6 days ago
| Entity Name | Davis Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619964806 PECOS PAC ID: 3072418540 Enrollment ID: O20040107000438 |
News Archive
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda (memantine hydrochloride) tablets, 5mg and 10mg.
"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.
Blue Cross and Blue Shield in Michigan won a hospital pricing antitrust case. In Minnesota, nonprofit insurer UCare prepares to return $8 million to the state while Blue Cross and Blue Shield of Minnesota's profit rose 20 percent in 2011.
› Verified 6 days ago
| Entity Name | Broaddus Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548246622 PECOS PAC ID: 5991692832 Enrollment ID: O20040413001625 |
News Archive
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda (memantine hydrochloride) tablets, 5mg and 10mg.
"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.
Blue Cross and Blue Shield in Michigan won a hospital pricing antitrust case. In Minnesota, nonprofit insurer UCare prepares to return $8 million to the state while Blue Cross and Blue Shield of Minnesota's profit rose 20 percent in 2011.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Catherine M Chua, DO 812 Gorman Ave, Elkins, WV 26241-3181 Ph: (304) 637-3894 | Dr Catherine M Chua, DO 812 Gorman Ave, Elkins, WV 26241-3181 Ph: (304) 637-0433 |
News Archive
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda (memantine hydrochloride) tablets, 5mg and 10mg.
"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.
An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of relapse after chemotherapy and metastasis. This drug, called Bozepinib, has proved to be effective in tests with mice.
NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.
Blue Cross and Blue Shield in Michigan won a hospital pricing antitrust case. In Minnesota, nonprofit insurer UCare prepares to return $8 million to the state while Blue Cross and Blue Shield of Minnesota's profit rose 20 percent in 2011.
› Verified 6 days ago
Dr. David Jay Currence, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 909 Gorman Ave, Suite #4, Elkins, WV 26241 Phone: 304-636-8886 Fax: 304-636-8805 | |
Dr. Ardel William Delgado Gorospe, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 | |
William C Dalton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 | |
Dr. Caren Lee Thompson, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 630 Robert E Lee Ave, Elkins, WV 26241 Phone: 304-637-8907 Fax: 304-637-3592 | |
Joel Thomas Hummer, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 | |
Misha Janelle Phillips-lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 Gorman Ave, Elkins, WV 26241 Phone: 304-636-3300 Fax: 304-637-3441 |